Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment

Journal of Pharmacy Practice

Volumn 24, Issue 3, 2011, Pages 345-350

  Koçkaya, Güvenç ^a,c   Wertheimer, Albert ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b TEMPLE UNIVERSITY   (United States)

^c Mesrutiyet M Yeni Ilhan S   (Turkey)

Author keywords

cardiology; internal medicine

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATIENT COMPLIANCE; RISK REDUCTION; STROKE; UNITED STATES;

EID: 79958079391     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010389336     Document Type: Article

References (18)

1. Center for Diseases Control and Prevention, Center for Diseases Control and Prevention's Statistics. Available athttp://www.cdc.gov/DataStatistics.
2. American Heart Association, Statistical Fact Sheet-Disease/Risk Factors 2010 Update. Available athttp://www.americanheart.org/presenter.jhtml? identifier=1200026. Accessed March 1, 2010.
3. Center for Diseases Control and Prevention, Diseases and Conditions Index-Heart Disease. Available athttp://www.cdc.gov/nchs/fastats/heart.htm. Accessed March 1, 2010.
4. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham Study. 1969. Chest. 2009 ; 136 (5 suppl). e23
5. Knight EL, Bohn RL, Wang PS, et al. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension. 2001 ; 38: 809-814 (Pubitemid 34258675)
6. American Heart Association, High Blood Pressure Risk Calculator. Available athttp://www.americanheart.org/beatyourrisk/en-US/main.html. Accessed March 1, 2010.
7. Center for Diseases Control and Prevention, Diseases and Conditions A-Z Index. Available athttp://www.cdc.gov/DiseasesConditions/az/a.html. Accessed March 1, 2010.
8. American Heart Association, Heart Disease and Stroke Statistics 2009 Update: A Report From the American Heart Association. Available athttp://circ.ahajournals.org/cgi/content/full/119/3/e21. Accessed March 1, 2010.
9. United States Renal Data System, Atlas of Chronic Kidney Diseases. Available athttp://www.usrds.org/2009/slides/indiv/INDEX-CKD.HTML. Accessed March 1, 2010.
10. Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manage Care. 2009 ; 15 (2 suppl). S36 - S41
11. Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics. 2001 ; 19 (12). 1185-1197 (Pubitemid 34074782)
12. Taylor AA. Combination drug treatment of hypertension: have we come full circle?. Curr Cardiol Rep. 2004 ; 6 (6). 421-426 (Pubitemid 39585759)
13. Blouin J, Dragomir A, Fredette M, et al. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int. 2009 ; 20 (9). 1571-1581
14. Nichol MB, Knight TK, Wu J, et al. Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications. Value Health. 2009 ; 12 (4). 544-550
15. Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009 ; 9 (11). 2597-2606
16. Almas A, Hameed A, Ahmed B, et al. Compliance to antihypertensive therapy. J Coll Physicians Surg Pak. 2006 ; 16 (1). 23-26
17. Chobanian AV. Improved hypertension control. JAMA. 2010 ; 303 (20). 2082-2083
18. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010 ; 303 (20). 2043-2050